​
​

Milestone Pharmaceuticals (MIST) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MIST Stock Forecast

Milestone Pharmaceuticals stock forecast is as follows: an average price target of $10.00 (represents a 437.63% upside from MIST’s last price of $1.86) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

MIST Price Target

The average price target for Milestone Pharmaceuticals (MIST) is $10.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 437.63% upside from MIST's last price of $1.86.

MIST Analyst Ratings

Buy

According to 4 Wall Street analysts, Milestone Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for MIST stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Milestone Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 22, 2022-Piper Sandler$10.00$7.1539.86%437.63%
Row per page
Go to

The latest Milestone Pharmaceuticals stock forecast, released on Apr 22, 2022 by Piper Sandler company, set a price target of $10.00, which represents a 39.86% increase from the stock price at the time of the forecast ($7.15), and a 437.63% increase from MIST last price ($1.86).

Milestone Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.86$1.86$1.86
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Milestone Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Milestone Pharmaceuticals's last price of $1.86. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Cowen & Co.BuyBuyHold
Oct 14, 2024H.C. WainwrightBuyBuyHold
Aug 22, 2024Rodman & Renshaw-BuyInitialise
Jul 02, 2024H.C. WainwrightBuyBuyHold
Dec 27, 2023Cowen & Co.OutperformOutperformHold
Apr 26, 2022Piper Sandler-OverweightUpgrade
Row per page
Go to

Milestone Pharmaceuticals's last stock rating was published by Cowen & Co. on Oct 21, 2024. The company gave MIST a "Buy" rating, the same as its previous rate.

Milestone Pharmaceuticals Financial Forecast

Milestone Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 22Jun 21
Revenue-------$3.50M$15.00M
Avg Forecast$3.82M$1.71M$433.33K$433.33K---$1.17M$5.00M
High Forecast$3.82M$1.71M$433.33K$433.33K---$1.17M$5.00M
Low Forecast$3.82M$1.71M$433.33K$433.33K---$1.17M$5.00M
# Analysts1111---11
Surprise %-------3.00%3.00%

Milestone Pharmaceuticals's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. MIST's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $3.50M (Dec 22).

Milestone Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 22Jun 21
# Analysts1111---11
EBITDA-------$-13.76M$793.00K
Avg Forecast$-763.80K$-342.60K$-86.67K$-86.67K---$-233.33K$-1000.00K
High Forecast$-763.80K$-342.60K$-86.67K$-86.67K---$-233.33K$-1000.00K
Low Forecast$-763.80K$-342.60K$-86.67K$-86.67K---$-233.33K$-1000.00K
Surprise %-------58.97%-0.79%

1 analysts predict MIST's average Quarter EBITDA for Dec 22 to be $-233.33K, with a high of $-233.33K and a low of $-233.33K. This is -129.42% lower than Milestone Pharmaceuticals's previous annual EBITDA (Jun 21) of $793.00K.

Milestone Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 22Jun 21
# Analysts1111---11
Net Income-------$18.26M$770.00K
Avg Forecast$-16.88M$-16.55M$-15.39M$-13.24M$-10.33M$-10.76M$-12.57M$-22.17M$-17.20M
High Forecast$-16.88M$-16.55M$-15.39M$-9.63M$-9.64M$-10.76M$-12.57M$-22.17M$-17.20M
Low Forecast$-16.88M$-16.55M$-15.39M$-18.05M$-11.70M$-10.76M$-12.57M$-22.17M$-17.20M
Surprise %--------0.82%-0.04%

Milestone Pharmaceuticals's average Quarter net income forecast for Jun 24 is $-12.57M, with a range of $-12.57M to $-12.57M. MIST's average Quarter net income forecast represents a -168.85% decrease compared to the company's last Quarter net income of $18.26M (Dec 22).

Milestone Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 22Jun 21
# Analysts1111---11
SG&A-------$6.68M$4.86M
Avg Forecast$30.02M$13.46M$3.41M$3.41M---$9.17M$38.80M
High Forecast$30.02M$13.46M$3.41M$3.41M---$9.17M$38.80M
Low Forecast$30.02M$13.46M$3.41M$3.41M---$9.17M$38.80M
Surprise %-------0.73%0.13%

Milestone Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to MIST last annual SG&A of $6.68M (Dec 22).

Milestone Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 22Jun 21
# Analysts1111---11
EPS-------$0.43$0.02
Avg Forecast$-0.26$-0.25$-0.23$-0.20$-0.16$-0.16$-0.19$-0.34$-0.26
High Forecast$-0.26$-0.25$-0.23$-0.15$-0.15$-0.16$-0.19$-0.34$-0.26
Low Forecast$-0.26$-0.25$-0.23$-0.27$-0.18$-0.16$-0.19$-0.34$-0.26
Surprise %--------1.28%-0.08%

According to 0 Wall Street analysts, Milestone Pharmaceuticals's projected average Quarter EPS for Jun 24 is $-0.19, with a low estimate of $-0.19 and a high estimate of $-0.19. This represents a -144.19% decrease compared to MIST previous annual EPS of $0.43 (Dec 22).

Milestone Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IVAInventiva$2.74$36.001213.87%Buy
XFORX4 Pharmaceuticals$0.34$3.67979.41%Buy
SPROSpero Therapeutics$1.20$10.00733.33%Buy
CHRSCoherus BioSciences$1.10$9.00718.18%Hold
LIFEaTyr Pharma$1.90$11.00478.95%Buy
MISTMilestone Pharmaceuticals$1.86$10.00437.63%Buy
CMPXCompass Therapeutics$1.37$5.00264.96%Buy
IKTInhibikase Therapeutics$1.98$6.50228.28%Buy
DAWNDay One Biopharmaceuticals$13.62$38.80184.88%Buy
TERNTerns Pharmaceuticals$5.60$14.25154.46%Buy
CGEMCullinan Oncology$12.58$31.50150.40%Buy
DMACDiaMedica Therapeutics$4.02$8.33107.21%Buy
NAMSNewAmsterdam Pharma Company$20.01$36.5082.41%Buy
BOLTBolt Biotherapeutics$0.57$1.0075.44%Hold
MCRBSeres Therapeutics$0.81$1.2554.32%Buy
HOOKHOOKIPA Pharma$2.72$3.0010.29%Buy
GRCLGracell Bio$10.25$6.00-41.46%Buy

MIST Forecast FAQ

Is Milestone Pharmaceuticals a good buy?

Yes, according to 4 Wall Street analysts, Milestone Pharmaceuticals (MIST) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of MIST's total ratings.

What is MIST's price target?

Milestone Pharmaceuticals (MIST) average price target is $10 with a range of $10 to $10, implying a 437.63% from its last price of $1.86. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Milestone Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for MIST stock, the company can go up by 437.63% (from the last price of $1.86 to the average price target of $10), up by 437.63% based on the highest stock price target, and up by 437.63% based on the lowest stock price target.

Can Milestone Pharmaceuticals stock reach $3?

MIST's average twelve months analyst stock price target of $10 supports the claim that Milestone Pharmaceuticals can reach $3 in the near future.

What are Milestone Pharmaceuticals's analysts' financial forecasts?

Milestone Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-33.653M (high $-32.965M, low $-35.03M), average SG&A $0 (high $0, low $0), and average EPS is $-0.508 (high $-0.498, low $-0.529). MIST's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.4M (high $6.4M, low $6.4M), average EBITDA is $-1.28M (high $-1.28M, low $-1.28M), average net income is $-62.053M (high $-58.443M, low $-66.867M), average SG&A $50.3M (high $50.3M, low $50.3M), and average EPS is $-0.938 (high $-0.883, low $-1.01).

Did the MIST's actual financial results beat the analysts' financial forecasts?

Based on Milestone Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $5M, beating the average analysts forecast of $1.17M by 328.57%. Apple's EBITDA was $-59.642M, beating the average prediction of $-233K by 25460.89%. The company's net income was $-57.134M, beating the average estimation of $-22.174M by 157.67%. Apple's SG&A was $24.81M, beating the average forecast of $9.17M by 170.57%. Lastly, the company's EPS was $-1.35, beating the average prediction of $-0.335 by 302.99%. In terms of the last quarterly report (Dec 2022), Milestone Pharmaceuticals's revenue was $3.5M, beating the average analysts' forecast of $1.17M by 200.00%. The company's EBITDA was $-13.759M, beating the average prediction of $-233K by 5796.72%. Milestone Pharmaceuticals's net income was $18.26M, missing the average estimation of $-22.174M by -182.34%. The company's SG&A was $6.68M, missing the average forecast of $9.17M by -27.15%. Lastly, the company's EPS was $0.43, missing the average prediction of $-0.335 by -228.36%